KR102759317B1 - 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물 - Google Patents

재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물 Download PDF

Info

Publication number
KR102759317B1
KR102759317B1 KR1020197007510A KR20197007510A KR102759317B1 KR 102759317 B1 KR102759317 B1 KR 102759317B1 KR 1020197007510 A KR1020197007510 A KR 1020197007510A KR 20197007510 A KR20197007510 A KR 20197007510A KR 102759317 B1 KR102759317 B1 KR 102759317B1
Authority
KR
South Korea
Prior art keywords
nucleic acid
delete delete
promoter
raav
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197007510A
Other languages
English (en)
Korean (ko)
Other versions
KR20190055086A (ko
Inventor
제프리 에스. 발트렛
Original Assignee
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 filed Critical 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드
Priority to KR1020237029234A priority Critical patent/KR20230130155A/ko
Publication of KR20190055086A publication Critical patent/KR20190055086A/ko
Application granted granted Critical
Publication of KR102759317B1 publication Critical patent/KR102759317B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020197007510A 2016-08-19 2017-08-18 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물 Active KR102759317B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237029234A KR20230130155A (ko) 2016-08-19 2017-08-18 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377297P 2016-08-19 2016-08-19
US62/377,297 2016-08-19
PCT/US2017/047589 WO2018035451A1 (en) 2016-08-19 2017-08-18 Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237029234A Division KR20230130155A (ko) 2016-08-19 2017-08-18 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물

Publications (2)

Publication Number Publication Date
KR20190055086A KR20190055086A (ko) 2019-05-22
KR102759317B1 true KR102759317B1 (ko) 2025-01-31

Family

ID=61197123

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197007510A Active KR102759317B1 (ko) 2016-08-19 2017-08-18 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물
KR1020237029234A Ceased KR20230130155A (ko) 2016-08-19 2017-08-18 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237029234A Ceased KR20230130155A (ko) 2016-08-19 2017-08-18 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물

Country Status (9)

Country Link
US (2) US11207382B2 (enExample)
EP (1) EP3500278B1 (enExample)
JP (2) JP7165410B2 (enExample)
KR (2) KR102759317B1 (enExample)
CN (1) CN109843306A (enExample)
AU (1) AU2017313844B2 (enExample)
CA (1) CA3073137A1 (enExample)
ES (1) ES2982489T3 (enExample)
WO (1) WO2018035451A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102759317B1 (ko) 2016-08-19 2025-01-31 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물
MX2019006614A (es) * 2016-12-07 2019-10-15 Univ Florida Adnc del antagonista del receptor de interleucina-1.
US12480138B2 (en) 2018-01-17 2025-11-25 MeiraGTx Gene Regulation Limited Modified rAAV capsid protein for gene therapy
US12370240B2 (en) 2018-11-28 2025-07-29 Genascence Corporation Methods and compositions for treating osteoarthritis
SG11202108614QA (en) 2019-02-15 2021-09-29 Sangamo Therapeutics Inc Compositions and methods for producing recombinant aav
HRP20241647T1 (hr) * 2019-07-15 2025-02-14 Meiragtx Uk Ii Limited Modificirani proteini aav kapsida za liječenje artritične bolesti
AU2020416291A1 (en) * 2019-12-31 2022-07-21 Swanbio Therapeutics Limited Improved AAV-ABCD1 constructs and use for treatment or prevention of adrenoleukodystrophy (ALD) and/or adrenomyeloneuropathy (AMN)
TW202525832A (zh) 2023-08-31 2025-07-01 美商戴諾治療公司 衣殼多肽及其使用方法(二)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008132485A2 (en) 2007-05-01 2008-11-06 Alligator Bioscience Ab Mutants of interleukin- 1 receptor antagonist and uses thereof
CN103509100A (zh) 2012-06-15 2014-01-15 上海百迈博制药有限公司 一种白细胞介素-1受体拮抗剂突变体

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156304A (en) 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US5747072A (en) * 1993-07-30 1998-05-05 University Of Michigan Adenoviral-mediated gene transfer to synovial cells in vivo
CA2155929A1 (en) * 1993-12-14 1995-06-22 Christopher H. Evans Systemic gene treatment of connective tissue diseases
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
DE69824859T2 (de) 1997-04-14 2005-08-04 Cell Genesys, Inc., Foster City Methoden zur erhöhung der effizienz rekombinanter aav produkte
AU9319198A (en) 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
ES2374290T3 (es) 1998-03-20 2012-02-15 Commonwealth Scientific And Industrial Research Organisation Genes sintéticos y constructos genéticos que comprenden los mismos.
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
PT1180159E (pt) 1999-05-28 2008-12-05 Targeted Genetics Corp Métodos e composições para abaixamento do nível de factor de necrose tumoral (tnf) nos distúrbios associados a tnf
US6429001B1 (en) 2000-01-26 2002-08-06 Chiron Corporation Recombinant AAV packaging systems
ES2256265T3 (es) 2000-06-01 2006-07-16 University Of North Carolina At Chapel Hill Vectores de parvovirus duplicados.
DE10056210A1 (de) 2000-11-13 2002-05-29 Arimedes Biotechnology Gmbh Virales Expressionssystem
JP2004519230A (ja) * 2001-02-06 2004-07-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 低減された免疫原性を有する修飾されたインターロイキン−１受容体アンタゴニスト（ｉｌ−１ｒａ）
KR100472297B1 (ko) 2001-09-27 2005-03-07 주식회사 두산 리소인지질의 수용성 조성물
KR100471942B1 (ko) 2002-03-19 2005-03-09 주식회사 에스원 복합형 카드와 카드정보 등록 제어시스템
DE10318048A1 (de) 2003-04-17 2004-11-04 Axaron Bioscience Ag Nicht fluoreszierende, durch Proteolyse zur Fluoreszenz aktivierbare Reporterproteine und ihre Verwendung zur Detektion Protease-abhängiger Ereignisse
US8529885B2 (en) 2003-09-01 2013-09-10 Academisch Medisch Centrum AAV vectors for in vivo gene therapy of rheumatoid arthritis
US20070009899A1 (en) 2003-10-02 2007-01-11 Mounts William M Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
CA2591544A1 (en) 2004-12-15 2006-06-22 The University Of North Carolina At Chapel Hill Chimeric vectors
US7943374B2 (en) * 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
FR2891544A1 (fr) 2005-09-30 2007-04-06 Genethon Ass Loi De 1901 Substrat proteique pour la detection de l'activite calpaine 3
WO2007112001A2 (en) 2006-03-23 2007-10-04 Caritas St. Elizabeth Medical Center Of Boston, Inc. Compositions and methods for treating myocardial infarction
JP2009534394A (ja) 2006-04-21 2009-09-24 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 結合組織障害の治療
US20080187576A1 (en) * 2006-06-16 2008-08-07 University Of Florida Research Foundation, Inc. Methods for treating articular disease or dysfunction using self-complimentary adeno-associated viral vectors
US20080166762A1 (en) 2006-09-27 2008-07-10 Reliance Life Science Pvt.Ltd. HETEROLOGOUS PRODUCTION OF INTERLEUKIN 1 RECEPTOR ANTAGONIST (IL-1Ra) IN PICHIA PASTORIS
US7452696B2 (en) 2006-10-27 2008-11-18 National Taiwan University Recombinant plasmid and method for expressing hepatitis B viral antigens and virions in vivo
JP5575486B2 (ja) 2007-01-18 2014-08-20 ユニヴァーシティ オブ ミズーリー−コロンビア 筋鞘にｎＮＯＳを回復させる合成ミニ／ミクロジストロフィン遺伝子
CA2740598C (en) * 2008-11-17 2018-05-22 Mathura P. Ramanathan Antigens that elicit immune response against flavivirus and methods of using same
WO2010121010A2 (en) 2009-04-16 2010-10-21 President And Fellows Of Harvard College Methods for inhibiting starvation of a cell
WO2011041309A1 (en) 2009-09-29 2011-04-07 Arresto Biosciences, Inc Methods and compositions for treatment of ocular fibrosis
DE202009017772U1 (de) 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
EP2394667A1 (en) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
WO2012047093A1 (en) 2010-10-05 2012-04-12 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of the sjögren's syndrome
KR101333958B1 (ko) * 2010-10-20 2013-11-27 주식회사 한독 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
US8736207B2 (en) 2011-01-03 2014-05-27 General Electric Company Method and system for power conversion
JP5918275B2 (ja) 2011-02-08 2016-05-18 アッヴィ・インコーポレイテッド 変形性関節症及び疼痛の治療
US20130021786A1 (en) 2011-07-21 2013-01-24 Noble Matthew D Utility bag lighting
PL2623604T3 (pl) * 2012-02-02 2015-07-31 Baylor College Medicine Biologiczny system dostarczania i ekspresji oparty na adenowirusie do zastosowania w leczeniu choroby zwyrodnieniowej stawów
US9878056B2 (en) * 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US20140162319A2 (en) 2012-05-02 2014-06-12 Sangeetha Hareendran Nucleotide sequences, methods, kit and a recombinant cell thereof
US9624282B2 (en) 2012-11-26 2017-04-18 The Curators Of The University Of Missouri Microdystrophin peptides and methods for treating muscular dystrophy using the same
PL2948553T3 (pl) * 2013-01-25 2020-11-16 Baylor College Of Medicine Adenowirusowy system dostarczania i ekspresji terapii genowej zależny od pomocnika
US10640771B2 (en) 2013-04-17 2020-05-05 Genzyme Corporation Compositions and methods for treating and preventing macular degeneration
EP2792742A1 (en) 2013-04-17 2014-10-22 Universitätsklinikum Hamburg-Eppendorf (UKE) Gene-therapy vectors for treating cardiomyopathy
DE102013215817A1 (de) 2013-08-09 2015-02-12 Universitätsklinikum Hamburg-Eppendorf Neue peptide mit spezifität für die lunge
PL3702466T3 (pl) 2013-08-27 2023-04-24 Research Institute At Nationwide Children's Hospital Produkty i sposoby do leczenia stwardnienia zanikowego bocznego
US20160354489A1 (en) 2013-09-26 2016-12-08 Universitat Autònome de Barcelona Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
DE102013220859B4 (de) 2013-10-15 2016-09-08 Plasmidfactory Gmbh & Co. Kg Minicircles mit viralen Expressionskassetten und ihre Verwendung zur Transformation von Zellen zur Erzeugung rekombinanter Viren oder viraler Genvektoren
JP6635942B2 (ja) 2014-04-15 2020-01-29 アプライド ジェネティック テクノロジーズ コーポレイション 網膜色素変性症ｇｔｐアーゼレギュレーター（ｒｐｇｒ）をコードするコドン最適化核酸
DE102014207498A1 (de) 2014-04-17 2015-10-22 Universitätsklinikum Hamburg-Eppendorf Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark
EP4600255A3 (en) 2014-05-02 2025-10-22 Genzyme Corporation Aav vectors for retinal and cns gene therapy
KR102759317B1 (ko) 2016-08-19 2025-01-31 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물
WO2018035457A1 (en) 2016-08-19 2018-02-22 Calimmune, Inc. Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus
EP3503928A4 (en) * 2016-08-19 2020-03-18 Colorado State University Research Foundation METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANINE CONDITIONS USING A RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS.
MX2019006614A (es) * 2016-12-07 2019-10-15 Univ Florida Adnc del antagonista del receptor de interleucina-1.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008132485A2 (en) 2007-05-01 2008-11-06 Alligator Bioscience Ab Mutants of interleukin- 1 receptor antagonist and uses thereof
CN103509100A (zh) 2012-06-15 2014-01-15 上海百迈博制药有限公司 一种白细胞介素-1受体拮抗剂突变体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Gene Therapy. 2004. Vol.11, pp.581-590.*
Gene Therapy. 2015. Vol.22, pp.536-545.*
Molecular Therapy-Nucleic Acids. 2013. Vol.2, e70.*

Also Published As

Publication number Publication date
KR20230130155A (ko) 2023-09-11
CA3073137A1 (en) 2018-02-22
JP2019524890A (ja) 2019-09-05
JP7653150B2 (ja) 2025-03-28
CN109843306A (zh) 2019-06-04
ES2982489T3 (es) 2024-10-16
JP2022130745A (ja) 2022-09-06
US20220175887A1 (en) 2022-06-09
EP3500278B1 (en) 2024-05-22
EP3500278A1 (en) 2019-06-26
US11207382B2 (en) 2021-12-28
AU2017313844A1 (en) 2019-04-11
WO2018035451A1 (en) 2018-02-22
EP3500278A4 (en) 2020-04-01
AU2017313844B2 (en) 2023-10-12
US20190381140A1 (en) 2019-12-19
JP7165410B2 (ja) 2022-11-04
KR20190055086A (ko) 2019-05-22
EP3500278C0 (en) 2024-05-22

Similar Documents

Publication Publication Date Title
KR102759317B1 (ko) 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물
CN115038789A (zh) 治疗性编辑
AU2021200988A1 (en) Gene therapy for retinitis pigmentosa
CN112105389B (zh) 用于转染抵抗细胞类型的组合物
CN114591989B (zh) 融合rna及其外泌体递送系统
CN109415429B (zh) Herv-e反应性t细胞受体及使用方法
CN110944656B (zh) 编码人类fkrp蛋白的新型多核苷酸
CN108753807B (zh) 一种重组嵌合抗原受体基因及其应用
CN111239386B (zh) 一种靶向抑制维生素K依赖性γ-谷氨酰羧化酶的小分子化合物的筛选方法及应用
AU2022214501B2 (en) Pharmaceutical composition for treating liver diseases using ssu72
CN114875067B (zh) Bestrophin3血管平滑肌特异性基因敲除小鼠和主动脉夹层小鼠模型的构建方法
CN113046369B (zh) 一种新型冠状病毒的mRNA疫苗
HK40009692A (en) Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus
KR102441384B1 (ko) 피부 미백 물질의 스크리닝 방법
CN103864902B (zh) 一种双价dna疫苗连接肽及其应用
US20040077573A1 (en) Method for regulating the activity of an expression product of a gene transferred into living body
CN115429796A (zh) 利鲁唑靶向治疗Wolfram综合征
CN110115770B (zh) 一种防治丙型病毒性肝炎的新靶点及其CRISPR-Cas9靶向系统与应用
US20240263143A1 (en) Baby Hamster Kidney (BHK) Cells Transformed with the Adenoviral E1 Gene for Production of Recombinant Adeno-Associated Virus
CN111560392B (zh) miRNA表达载体及其应用
US20040076636A1 (en) HIV immunogenic complexes
CN114480398A (zh) siRNA及其在制备改善和/或治疗白癜风的药物中的应用
CN116769811A (zh) 分泌trail的工程化巨噬细胞及其应用
CN112852869A (zh) 一种构建四肢畸形小鼠模型的方法
CN115747213A (zh) 一种在基因组上高通量实现tag到taa转换的方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190314

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PN2301 Change of applicant

Patent event date: 20200811

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200818

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220819

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230327

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220819

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20230828

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20230327

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2023101001844

Request date: 20230828

J301 Trial decision

Free format text: TRIAL NUMBER: 2023101001844; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20230828

Effective date: 20241023

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20241023

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20230828

Decision date: 20241023

Appeal identifier: 2023101001844

PS0901 Examination by remand of revocation

Patent event code: PS09011S01I

Patent event date: 20241023

Comment text: Notice of Trial Decision (Remand of Revocation)

S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20241028

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250120

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250121

End annual number: 3

Start annual number: 1

PG1601 Publication of registration